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Abstract
We examined the feasibility and acceptability of using an immersive virtual reality environment (VRE) alongside cogni-
tive behaviour therapy (CBT) for young people with autism experiencing specific phobia. Thirty-two participants were 
randomised to treatment or control. Treatment involved one session introducing CBT techniques and four VRE sessions, 
delivered by local clinical therapists. Change in target behaviour was independently rated. Two weeks after treatment, four 
treatment participants (25%) and no control participants were responders; at 6 months after treatment, six (38%) treatment 
and no control participants were responders. At 6 months post-treatment, symptoms had worsened for one treatment and five 
control (untreated) participants. Brief VRE exposure with CBT is feasible and acceptable to deliver through child clinical 
services and is effective for some participants.
Keywords Autism · Anxiety · Phobia · Fear · Virtual reality · Cognitive behaviour therapy
Introduction
Autism spectrum disorder (ASD) occurs in around 1% of 
the population and is characterised by social communication 
difficulties and repetitive behaviours (American Psychiatric 
Association 2013; Baird et al. 2006). Co-existing conditions 
are common in ASD (Maskey et al. 2013) including anxiety, 
which affects around half of children (Simonoff et al. 2008; 
Maskey et al. 2013). In a clinical setting, anxiety is among 
the most common treatment referral reasons for young peo-
ple with ASD (Ghaziuddin et al. 2002). Specific phobia 
(defined by DSM-5 as extreme or irrational fear of an object/
situation) is one of the most common anxiety presentations 
in ASD (Leyfer et al. 2006; Mattila et al. 2010). Prevalence 
rates of 30–64% have been reported (Leyfer et al. 2006; van 
Steensel et al. 2011); rates are 5–18% in typically develop-
ing children (Ollendick et al. 2002). The nature of phobias 
for children with ASD may be ‘unusual’ or atypical, such 
as situation-specific fear (e.g. visiting a particular location), 
of everyday objects (toilets, machines, foods), or of people 
with certain personal characteristics (Mayes et al. 2013). 
Importantly these difficulties have an impact on the daily 
lives of the child and family, interfering with education and 
learning (Maskey et al. 2014) and have been associated with 
higher levels of challenging behaviours (Evans et al. 2005).
There are a range of treatments for phobias in typically 
developing individuals, with cognitive behaviour therapy 
(CBT) and graded exposure as key therapeutic techniques 
(Ollendick et al. 2006). However, these techniques may not 
be as effective for some children with ASD. For example, 
graded exposure typically begins with imaginal desensiti-
sation; many individuals with ASD experience difficulties 
 * Jeremy R. Parr 
 jeremy.parr@ncl.ac.uk
1 Institute of Neuroscience, Sir James Spence Institute 
Level 3, Royal Victoria Infirmary, Newcastle University, 
Newcastle upon Tyne NE1 4LP, UK
2 Complex Neurodevelopmental Disorders Service, 
Northumberland Tyne and Wear NHS Foundation Trust, 
Newcastle upon Tyne, UK
3 Newcastle University, Newcastle upon Tyne, UK
4 Business Development and Enterprise, Faculty of Medical 
Sciences, Newcastle University, Newcastle upon Tyne, UK
5 Tees Esk and Wear Valley NHS Foundation, Trust, UK
6 Institute of Health and Society, Newcastle University, 
Newcastle upon Tyne, UK
 Journal of Autism and Developmental Disorders
1 3
with imagination (Lind et al. 2014) such as producing and 
controlling imaginal scenes. This may be a challenge or bar-
rier to treatment adherence and/or effectiveness. National 
Institute for Health and Care Excellence (NICE) ASD man-
agement guidance in the UK specifies that CBT will require 
adaptation to increase the likelihood of effectiveness for 
individuals with ASD (NICE 2013). Suggested adaptations 
include the development of disorder-specific hierarchies, 
the use of more concrete visual tactics, incorporation of a 
child’s specific interests, and inclusion of parents in treat-
ment (Moree and Davis 2010); additional adaptations may 
include psychoeducation about recognising and understand-
ing emotions, problem solving, and a reduced cognitive 
component with greater use of behavioural strategies such 
as exposure and relaxation. Research indicates that with such 
adaptations, CBT based interventions can be successful in 
promoting anxiety reduction for individuals on the autism 
spectrum (Lang et al. 2010; Ung et al. 2015).
Increasingly, new technologies, such as virtual reality 
(VR), are being used with the neurotypical population to 
augment traditional psychological treatments (Hollis et al. 
2016; Freeman et al. 2017; Valmaggia et al. 2016). VR may 
be particularly helpful for the delivery of interventions for 
those with ASD because it allows simulations of real world 
situations to be created, and newly learned coping skills 
can be rehearsed and reinforced in a safe and controlled 
environment (Parsons and Cobb 2011). VR has been used 
successfully to improve various skills, for example, social 
understanding (Mitchell et al. 2007; Kandalaft et al. 2013), 
job interview skills (Smith et al. 2014), driving skills (Bian 
et al. 2013) and road safety and fire alarm procedures (Jos-
man et al. 2008; Strickland et al. 2007). For people with 
ASD and specific phobias, VR may offer an alternative to 
usual exposure hierarchies used in traditional CBT, which 
typically move through imaginal desensitisation to real life 
exposure. VR may facilitate a more gradual exposure to the 
feared stimulus in a controlled manner, whilst concurrently 
allowing the participant to be supported to develop anxiety 
management strategies with a therapist.
Given the potential utility of the combination of CBT 
and VR to the treatment of specific phobias for people with 
ASD, we aimed to investigate the combination of an immer-
sive virtual reality environment (VRE) alongside therapist-
delivered CBT to reduce anxiety. Maskey et.al. (2014), using 
a case study design with nine volunteer children who expe-
rienced specific phobias, reported the preliminary accept-
ability of an immersive VRE, known as the Blue Room, 
alongside CBT. The Blue Room is a fully immersive VRE 
without the need for a headset or goggles; the therapist 
controls the perceived movement through the scene with 
an iPad. Each child received four VRE twenty-minute treat-
ment sessions delivered over one week. Of nine volunteer 
children, eight children improved in their ability to tackle 
their real life specific phobia, as described in vignettes of 
behaviour and rated by an expert panel. These improvements 
were maintained at 12 months follow up. The specific pho-
bias addressed were related to everyday occurrences, such 
as travelling on public transport, and therefore overcoming 
these phobias significantly improved families’ daily lives 
(Maskey et al. 2014). Limitations included recruitment from 
a community based group rather than from clinical health 
services, lack of randomisation and a control group, and 
treatment delivery by the study team rather than within fami-
lies’ local health services.
In order to provide further evidence, we aimed to trial the 
VRE and CBT intervention reported in Maskey et al (2014) 
with a larger sample of children who were being seen in 
clinical services, randomising them to either a treatment or 
control group (delayed treatment). We report the results of 
the first Randomised Controlled Trial (RCT) of the Blue 
Room VRE intervention. The study aims were to (1) evalu-
ate treatment delivery feasibility, with fidelity, by thera-
pists from two UK National Health Service (NHS) teams; 
(2) determine acceptability of outcome measures to young 
people and parents; (3) investigate responses to the VRE 




This was a single blind RCT comparing a virtual reality 
treatment for specific phobias in children with ASD with 
usual care (immediate and control (delayed) treatment arms). 
After consent and baseline measures were taken, participants 
were randomised to one of these arms.
The immediate treatment group were followed up at 2 
weeks and 6 months after treatment. The control arm com-
pleted outcome measures at these time points. The control 
group then received the treatment after completing the meas-
ures at 6 months (see Consort Diagram); after their treat-
ment they were subsequently followed-up at 2 weeks and 
6 months post treatment. The immediate treatment group 
had one additional follow-up at 12 months post treatment.
Participants and Recruitment
Thirty-two young people with ASD were recruited over a 12 
month period from two UK mental health services—North-
umberland, Tyne and Wear NHS Foundation Trust and Tees, 
Esk and Wear Valley NHS Foundation Trust.
Inclusion criteria: Age 8–14 years, diagnosis of ASD, 
verbally fluent and able to understand instructions to enable 
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treatment participation and completion of outcome meas-
ures. Verbal fluency and comprehension were determined as 
part of usual clinical practice by the child’s clinical consult-
ant, who judged the child’s suitability for the study. All par-
ticipants had a specific phobia as identified during the Anxi-
ety Diagnostic Interview Schedule (ADIS) interview (see 
below). Exclusion criteria were participants whose phobia 
could not be visually represented and addressed in the Blue 
Room (e.g. phobia of injections), children with severe and 
complex anxiety disorder, and/or children with a learning 
disability that the referring mental health clinician judged 
would affect their ability to participate.
The child’s usual mental health clinician initially dis-
cussed the study with the family and then completed 
an expression of interest form and the Children’s Global 
Assessment Scale score (CGAS—a brief measure of emo-
tional and behavioural functioning, with range 1–100) (Shaf-
fer et al. 1983). All participants had a confirmed ASD diag-
nosis according to DSM-IV or ICD-10 criteria from NHS 
multidisciplinary diagnostic teams.
On receiving the Expression of Interest form, a member 
of the research team contacted families to evaluate whether 
their specific phobia was suitable for treatment and for com-
puter generated, graded scene design. Forty families were 
identified by clinicians; five of these did not have a phobia 
that could be treated in the Blue Room and three declined 
to take part after receiving further information. Thirty-two 
families received a preparatory home visit where baseline 
measures were completed and the family shown a video 
of the Blue Room VRE; written informed consent was 
obtained. Table 1 shows the characteristics of participants. 
The two groups were well matched for mean age and gender 
and on outcomes captured by the standardised measures. 
Table 2 shows the specific phobias that were identified by 
participants and their families as the target to address during 
the Blue Room treatment.
Measures
Baseline Characterisation
The following measures were completed by the participant 
and their parent/caregiver at baseline.
Social Communication Questionnaire (SCQ) (Berument 
et  al. 1999) A parent-completed 40 item questionnaire to 
describe the child’s ASD characteristics. It is used interna-
tionally, and has high sensitivity and specificity for an ASD 
diagnosis.
Anxiety Disorders Interview Schedule (ADIS) (Silverman 
1996) A widely used standardised clinical interview carried 
out with parents; each anxiety area is given a severity rating, 
including separation anxiety, social anxiety disorder, spe-
cific phobia, panic disorder, obsessive–compulsive disorder 
and generalised anxiety disorder.
Vineland Adaptive Behaviour Scales (VABS) (Sparrow et al. 
2005) This parent interview allows children’s functional 
abilities to be compared to age norms (Communication, 
Socialisation and Daily Living Skills). We did not undertake 
IQ assessment as feasibility must relate to current clinical 
practice, where clinicians take pragmatic decisions about 
treatment and children’s capabilities rather than basing 
treatment access on assessment scores.
Outcome Measures
Maskey et al (2014) reported that Target Behaviour ratings 
are appropriate outcome measures of real life change in 
behaviours of concern. This is further supported in a review 
of the treatment of specific fears and phobias in children 
with ASD (Lydon et al. 2015), where target behaviours were 
found to be the primary outcome measure in 10 of the 16 
studies reviewed. This measure was therefore included as 
the main outcome measure, alongside questionnaires, to 
investigate the utility of different outcome measures with 
this clinical population.
For the treatment and control groups the following out-
come measures were collected:
Target Behaviour rating This measure recorded a rat-
ing of change over time in the specific phobia to be tackled 
through Blue Room treatment. The protocol was developed 
by the Research Units on Paediatric Psychopharmacology 
(RUPP) Autism Network (Arnold et al. 2003). Questions 
regarding the child’s specific phobia behaviours, and ques-
tions such as ‘how often?’ and ‘how distressed?’ were asked 
in a standard format to the parent, enabling a vignette to 
be written. Following an interview about phobia during 
the initial home visit, pre-treatment vignettes were writ-
ten prior to randomisation, by the first author (for examples 
see Table 5). These baseline vignettes are not rated per se, 
but rather serve as a baseline from which Target Behav-
iour change is measured. Follow-up vignettes were written 
from telephone interviews with parents, undertaken by the 
blinded outcome assessor. All efforts were made to maintain 
the assessor as blinded. Each vignette pair (baseline vs post 
treatment vignettes) was evaluated for change over time on 
a 9 point scale (from ‘normalised’ to ‘disastrously worse’). 
An expert panel of raters received training with examples, 
before rating the pairs of vignettes. Raters were blind to 
group allocation and time point, and each vignette pair was 
rated by four different raters. Arnold and colleagues (Arnold 
et al. 2003) reported an Intraclass Correlation Coefficient 
(ICC) of 0.895 for a panel of 5 experts; in this study ICCs 
for the two time points were 0.869 (95% CI 0.775 to 0.930) 
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and 0.935 (95% CI 0.887 to 0.965). The Target Behaviour 
rating is reported both dimensionally, and also by categori-
cal cut-score using a mean of 3.0 or less, corresponding to 
a rating of ‘definitely improved’ or better, to define positive 
treatment response (‘responders’). In addition, a cut-score 
of 6.0 or more was used in this study to define those whose 
symptoms had worsened compared to baseline.
Spence Children’s Anxiety Scale-parent version (SCAS-
P) and child version (SCAS-C) The SCAS (Spence 1998) 
was developed to assess anxiety symptoms in children in 
Table 1  Baseline characteristics 
of the immediate treatment and 
control groups
a SCQ Social Communication Questionnaire
b CGAS Children’s Global Assessment Scale








 Male 13 (81.3) 12 (75) 25 (78.1)
 Female 3 (18.8) 4 (25) 7 (21.9)
Age
 Mean (months) 130.13 (28.38) 129.00 (21.51) 129.56 (24.78)
 Range (months) 89–174 90–157 89–174
Ethnicity
 White 16 (100) 14 (87.5) 30 (93.8)
 Non white 2 (12.5) 2 (6.2)
Additional diagnoses
 Any 13 (81.3) 11 (68.8) 24 (67)
 Dyslexia 1 (6.3) 1 (6.3) 2 (6.3)
 Dyspraxia 3 (18.8) 4 (25.0) 7 (21.9)
 ADHD 4 (25.0) 4 (25.0) 8 (25.0)
 Other 5 (31.3) 2 (12.5) 7 (21.9)
Household income
 Above UK mean income 9 (56.3) 9 (56.3) 18 (56.3)
 Below UK mean income 6 (37.5) 7 (43.8) 13 (40.6)
 Prefer not to say 1 (6.3) 0 1 (3.1)
Information about parent who observed treatment
 Mother/Father (includes one grand-
mother)
15/1 (93.8/6.3) 14/2 (87.5/12.5) 29/3 (90.6/9.4)
 Married/cohabiting 12 (75.0) 13 (81.3) 25 (78.1)
 University degree 6 (37.5) 3 (18.8) 9 (28.1)
 Employed 10 (62.5) 9 (56.3) 19 (59.4)
SCQa score ≥ 15/<15 14/1 14/2 29/3
Mean SCQ score (SD) 25.07 (7.69)
(1 missing)
25.06 (7.59) 25.06 (7.51)
(1 missing)







 Specific phobia 14 (87.5) 14 (87.5) 28 (87.5)
 Social phobia 2 (12.5) 2 (12.5) 4 (12.5)
 Number with secondary diagnoses 
(mean number of secondary diagnoses 
per child)
14 (2.8) 14 (2.8) 28 (2.8)
 Mean Vineland scores (n = 14) (n = 16) (n = 30)
 Communication 73.50 (16.09) 73.63 (11.91) 73.57 (13.76)
 Daily living skills 72.07 (13.68) 65.44 (8.10) 68.57 (11.33)
 Socialisation 63.14 (10.38) 65.00 (14.97) 64.40 (12.27)
 Adaptive behaviour composite 68.43 (11.99) 66.63 (8.53) 67.53 (10.08)
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the general population and has 38 items with a 0 (never) 
to 3 (always) scale. The measure has been widely used in 
ASD studies (Sofronoff et al. 2005; Maskey et al. 2014). 
High internal consistency for the total scale score has been 
reported (Spence 1998), and both convergent and divergent 
validity (Nauta et al. 2004). In the current study, internal 
consistency at baseline was α = 0.900 for SCAS-P and 
α = 0.863 for SCAS-C.
Fear survey schedule for children—revised (FSSC-R) 
(Ollendick 1983) This is an 80 item parent-report question-
naire with an overall intensity and fearfulness score. The 
FSSC-R is the most commonly used tool for assessment of 
common fears and phobias, with good construct, conver-
gent and divergent validity (Gullone et al. 2000) and strong 
test–retest reliability and internal consistency (Burnham and 
Gullone 1997). In the current study, internal consistency at 
baseline was α = 0.932.
Children’s Assessment of Participation and Enjoyment 
(CAPE). This was completed by the child at baseline and 9 
months and intended to measure any increase in participa-
tion in community activities. CAPE is a 50 item child-report 
of activities, presented pictorially, to assess children’s partic-
ipation in a range of solitary and group voluntary activities. 
Reliability and validity of the CAPE was established through 
study of 427 children with disabilities (King et al. 2007).
Process Measures
Attendance: whether children attended all sessions was 
recorded.
Confidence ratings: during treatment children rated their 
confidence at tackling their goal situation at the beginning of 
session one, end of session two, beginning of session three 
and end of session four. Parents rated their perception of 
their child’s confidence at parallel time points. Ratings were 
from 0 (not comfortable) to 6 (very comfortable); parent and 
child ratings were taken in separate rooms and not shared. 
Examples of a confidence scale used are given in a previous 
publication (Maskey et al. 2014).
When families were approached but chose not to partici-
pate, ethical permission was granted to pass the following 
anonymised data to the research team: CGAS score, age, 
gender, ASD diagnosis and type of diagnosis. This was to 
allow ‘refusers’ to be characterised and compared with trial 
participants.
Randomisation and Masking
Participants were randomly allocated to immediate treatment 
group (n = 16) or control group, for whom treatment was 
offered after the 6 months outcome measures were admin-
istered (n = 16). Allocation was by computer using a pass-
word-protected Newcastle University Clinical Trials Unit 
website. Randomisation was by mixed block design, using 
block sizes of two and four, stratified by site. Due to the 
nature of the treatment, participants, clinicians and the main 
researcher for the study were aware of group allocation. 
Participants were randomised and informed after the initial 
home visit as to whether or not they were in the immediate 
treatment group. Another researcher, blind to treatment allo-
cation, conducted outcome measurements through telephone 
discussion of target behaviours with families and receiving 
postal questionnaires. Blinding was strictly maintained; this 
outcome assessor had no other trial role, no access to docu-
ments and did not attend trial meetings. At each telephone 
or postal contact, this outcome assessor reminded parents 
she was unaware of group allocation.
Materials
The Blue Room VRE is a patented immersive technology 
using interactive computer generated audio visual images 
projected onto the walls and ceilings of a 360 degree 
screened room (Fig. 1). The room was 4 m3 and the partici-
pant and therapist sit side by side. A therapist remains with 
the participant throughout the treatment sessions, deliver-
ing the CBT techniques (described below). Scenes are indi-
vidualised, incorporating an exposure hierarchy related to 
the feared stimulus. For example, for dog phobia, adaptions 
include the dog’s size, whether on or off a lead, barking, 
and proximity to the participant. This gradation allows the 
participant to experience levels of mastery in managing their 
anxiety and to repeatedly practice this at one level of chal-
lenge before moving to the next (Maskey et al. 2014). The 
Table 2  Specific phobias which were addressed (treatment group and 
control group)
a Anxiety related to very specific social situations that were identified 
by the child and their parents as highly desirable treatment targets
Treatment group phobias Control group phobias
Bananas Dogs (x2)
Wasps/bees (x2) Flying (x2)
Open spaces Wasps/bees
Dogs (x3) Specific chronological time
Lifts Heights/glass elevators (x2)
Fear of the dark Thunder and lightening
Insects Making  requestsa
Being looked  ata Mascots
Changes in weather Automated toys
Eating in front of other  peoplea Fear of the dark
Balloons Travelling in the car
Dolls Toilets
Bats Balloons
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following link shows a session in progress: https ://www.
youtu be.com/watch ?v=9U-rRC8j c28.
Treatment
Before VR sessions, each participant and parent attended 
a 45 minutes session with their allocated therapist. The 
therapist was a health professional (for example an assis-
tant psychologist, or a specialist nurse) with experience in 
ASD and/or CBT, who had attended the training workshop 
(see below). Simplified CBT techniques were introduced, 
including: (1) identifying feelings (how different parts of 
the body feel; how thoughts, emotions and behaviours are 
connected); (2) the concept of a visual ‘feeling thermom-
eter’ using the participant’s words to describe anxiety; (3) 
two relaxation exercises (muscle relaxation and deep breath-
ing, with scripts for home practice); (4) identification of the 
participant’s positive coping statement, e.g. ‘I can do this’, 
‘I’m going to be ok’, to use in the treatment sessions. These 
CBT elements were repeated and consolidated during VRE 
sessions. The goal for the end of treatment was agreed with 
the participant; this goal was used for the confidence rating 
charts for parent and participant.
Following scene creation, participants attended 20 min 
treatment sessions. Two Blue Room treatment sessions were 
completed at one visit, with a fifteen minute break between. 
The second two sessions were conducted around one week 
later. The therapist allocated to the participant was present 
during all sessions. Parents watched treatment via a video 
link, and the session content and purpose of activities was 
explained. For the first two sessions, a supervising qualified 
clinical psychologist attended to observe and give feedback 
to the therapist. This supervising therapist also answered any 
questions the family had during the session.
Materials for the treatment sessions (the treatment man-
ual, customised visual scales and relaxation scripts) were 
provided to therapists. Each Blue Room session started 
with a relaxation scene, allowing the participants to become 
familiar with the environment, and to practice relaxation 
techniques and coping self-statements. The two available 
relaxation scenes were of swimming dolphins, and a field 
in the country; scenes had soft background music that could 
be turned off if requested. The duration the child spent 
looking at these scenes and practising relaxation exercises 
was at the discretion of the therapist, as the aim was to be 
responsive to the needs of individual participants; for most 
participants, one cycle of muscle relaxation and breathing 
exercises was sufficient at the beginning of each session. 
The relaxation scenes were returned to during a session if 
the therapist thought the participant’s anxiety was severe 
or if the participant was finding it difficult to manage their 
anxiety during a particular scene.
Following the relaxation scenes, the participant was intro-
duced to the VRE scene designed for them. The initial scene 
was designed to be the lowest level of the exposure hierarchy 
for that participant (e.g. a quiet dog on a lead in the dis-
tance). The participant gradually moved through the hierar-
chy; they progressed to an increased level of challenge when 
Fig. 1  Picture of the Blue Room virtual reality environment
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they were consistently reporting low levels of anxiety (score 
of 2 or less on a six point scale) on the visual scale for a 
scene, and there was agreement between the participant and 
therapist to move on. At each level of the hierarchy, partici-
pants were supported by the therapist to practise techniques 
to reduce anxiety, including relaxation exercises, thought 
challenging and anxiety monitoring. If anxiety increased as 
the scene became more challenging, the therapist suggested 
relaxation and breathing exercises, moving to the relaxation 
scenes if needed. Progress through the scenes was deter-
mined by the progress participants made towards maintain-
ing low anxiety at each level and was individualised to each 
participant. After completing the fourth session, the therapist 
spoke with participants and their family regarding graded 
real world exposure to the anxiety situation. The therapist 
explained the need to gradually introduce the participant to 
the feared situation in real life and discussed various steps in 
the hierarchy of exposure relevant to the particular phobia.
Therapist Training and Treatment Fidelity 
Measurement
Before delivering treatment, local therapists read the manual 
and attended a 2 hours, group training workshop delivered 
by an experienced child clinical psychologist (author 10). 
The manual for the treatment is copyrighted and is available 
on request from the corresponding author. Training involved 
discussion of why children with ASD may develop anxi-
ety, explanation of the steps in treatment including evolu-
tion over four sessions, review of video material from live 
sessions, and individual practice with the tablet computer 
in the VRE.
All Blue Room treatment sessions were video recorded. A 
sample of 30% of sessions in the immediate treatment group 
were rated for fidelity to delivery as per the manual. The 
sessions were chosen at random but always included at least 
one session conducted by each of the 11 therapists, and an 
even spread of VRE sessions 1 to 4. Fidelity was recorded on 
a checklist to assess (a) Delivery of CBT best practice and 
(b) the manual Content and Structure [checklist designed by 
author 2, drawing on sources including Roth & Pilling (Roth 
and Pilling 2008)]. Delivery ratings included Techniques 
used (9 or 10 elements e.g. collaborative approach, mod-
elling reflection, using relaxation strategies, using praise), 
Generic Acceptable components (5 elements e.g. therapeutic 
alliance, managing emotional content, appropriate flexibil-
ity) and Undesirable components (6 elements e.g. didactic 
approach, allows off-topic deviation); Content and Structure 
included around 10 elements (e.g. setting agenda, summa-
rising, scenes presented in increasing levels of difficulty). 
Rating definitions and number varied between sessions for 
Techniques and Content, as different elements were intro-
duced or became irrelevant. Delivery ratings were: 0 (not at 
all), 1 (minimal evidence), 2 (several examples) with ratings 
reversed for Undesirable components. Content ratings were: 
0 (not covered), 1 (covered insufficiently) and 2 (covered 
adequately). Senior co-authors (authors 2, 3 and 10) estab-
lished mean inter-rater agreement at 83.6% for Techniques, 
96.0% for Acceptable and 92.2% for Undesirable compo-
nents. Agreement of mean 69.7% (range across raters and 
sessions 56–94%) for Content and Structure was lower so 
was not rated further. Content rating proved difficult for sev-
eral reasons: the quality of audio in recordings; some aspects 
perhaps being covered outside the VR; expectation that CBT 
would be flexibly individualised.
Analysis
Analysis was conducted according to a pre-specified sta-
tistical analysis plan. Post hoc testing of the main outcome 
measure found sensitive to change in our development study 
(Target Behaviour rating) was then conducted to explore 
potential efficacy.
Analysis was undertaken by author 4, blind to group sta-
tus and supervised by author 2.
Group equivalence at baseline was investigated using 
Fisher’s exact test, Pearson’s chi square and t-tests. Explor-
atory group comparison over time was made for the Tar-
get Behaviour ratings using Mann Whitney U test and chi 
square. Descriptive statistics (mean, standard deviation) are 
presented for all questionnaire data, along with effect size 
(Cohen’s d), where values 0.2, 0.5 and 0.8 indicate a small, 
medium, and large effect size respectively.
Collection of 12-month post treatment data from the treat-
ment group: To undertake a preliminary investigation of the 
medium term treatment effectiveness, children’s outcomes 
for the immediate treatment group were investigated 12 
months post treatment. Target behaviour follow-up vignettes 
were written following telephone interviews with parents; 
these were undertaken by the same blinded outcome assessor 
and vignettes written (questionnaire data were not collected 
at this timepoint to reduce the burden on parents). Vignettes 
were rated as described above by the blinded expert rater 
group. Descriptive data are reported separately from the 
main trial outcomes.
Treatment outcomes for the control (delayed treatment) 
group: After the wait phase and completion of measures at 
6 months, parents and children from the control group were 
offered VR treatment sessions. 15/16 parents accepted; one 
child was not treated as following discussion with the local 
treating clinician, it was agreed that due to family circum-
stances and generalised anxiety symptoms, phobia treatment 
was not the main priority. Fifteen children received treat-
ment according to the treatment plan described above. Out-
come measures were collected at 2 weeks and 6 months post 
treatment, and target behaviour interviews were undertaken 
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with parents; vignettes were written by the same outcome 
assessor, who at this stage was not blind as only control 
group data was being collected at this point. Questionnaire 
data were not collected. Vignettes were rated as described 
above by the expert rater group, who remained blind to 
group status. Descriptive data are reported separately from 
the main trial outcomes.
Approvals and Research Governance
A favourable ethical opinion was provided by the UK 
National Health Service Tyne and Wear South Ethics Com-
mittee (reference 14/NE/1177). The research sponsor was 
Northumberland, Tyne and Wear NHS Foundation Trust. 
The trial was conducted and reported in accordance with 
CONSORT guidelines, and was registered on the ISRCTN 
trial database (Trial ID: ISRCTN7886185). The trial team 
and co-applicants met regularly during the study. A parent 
advisory group met regularly to advise on trial procedures.
Results
Participants were recruited between March 2015 and Febru-
ary 2016. Thirty-two children, mean age 10 years 10 months, 
were recruited (25 boys and 7 girls); 16 children were allo-
cated to each trial arm. The baseline characteristics of chil-
dren from the immediate treatment and control groups are 
shown in Table 1. The two groups did not differ significantly 
on any measure of child and family demographics, the pres-
ence of additional diagnoses that commonly co-exist with 
ASD, nor baseline characterisation measures, i.e. children’s 
ASD symptom severity, anxiety diagnoses, level of adaptive 
behaviour, and overall functioning.
Some information was available from the children with 
ASD who were approached and chose not to participate 
or who did not have a suitable phobia to participate in the 
trial. This included 7 boys and 1 girl (mean age 11 years 
3 months). Three CGAS scores were available; the mean 
CGAS score for non-participants was 45.0 (SD 9.6), similar 
to the mean score of the total sample.
Feasibility and Acceptability
Figure 2 shows the flow of participants through the trial. 
All 32 participants completed the interview about the target 
behaviour at all time points. There was no attrition by six 
months. Data completeness for questionnaires was 89.0% at 
baseline and 82.8% at 6 months follow-up.
All children in the immediate treatment group completed 
four VRE treatment sessions.
For the immediate treatment group, most child and 
parent confidence ratings for tackling the goal situation 
increased between the start of session 1 and at the end of 
session 4 (Fig. 3a, b). The average fidelity of treatment 
delivery across sessions was very high at 94.5% (range 
91–96.5%). The overall mean fidelity for the eleven thera-
pists ranged from 84.5-100% indicating all therapists were 
at least adequate and most were excellent in style of deliv-
ery of the VRE CBT treatment.
Treatment Outcomes
Target Behaviour Rating
The treatment group showed a statistically significant 
greater improvement on Target Behaviour ratings com-
pared with the control group, for both baseline to two 
weeks post treatment (U = 67.5, p = 0.021) and baseline to 
six months post treatment (U = 53.0, p = 0.007) (Table 3) 
with large effect sizes.
Six out of 16 (38%) treatment group children were clas-
sified as responders six months after treatment, compared 
with no control group children (responders vs all others, 
χ2 = 6.98, p = 0.018) (Table 4). Four children in the treat-
ment group had responded at 2 weeks post treatment. It is 
important to note that, at 6 months, five children from the 
control group (31%) were rated as having symptoms worse 
than baseline; one of the immediate treatment group also 
showed symptoms worsening. Twelve months post treat-
ment data for the immediate treatment group were avail-
able from 11/15 children; four of these 11 children were 
treatment responders. Table 5 shows examples from edited 
vignettes at baseline, and 6 months post treatment, for 
three exemplar treatment group children (one responder, 
one no/equivocal change and the child whose symptoms 
were worse).
Questionnaire Measures (SCAS‑P, SCAS‑C, FSSC‑R, CAPE)
Questionnaire data (mean total scores, standard deviations 
and Cohen’s d at baseline and 6 months post baseline) for 
the treatment and control groups are presented in Table 6. 
None of the comparisons from baseline was statistically sig-
nificant (p values not shown). To compare groups’ mean 
questionnaire scores over time mixed factorial ANOVA were 
performed, with the group (control vs treatment) and time 
(baseline, 2 weeks post-treatment, 6 months post-treatment) 
entered as independent variables. All main effects of group 
and interactions between time and group were non-signifi-
cant for all the questionnaires’ scores. We present here the 6 
month outcome data for ease of reading.
Data from 2 weeks and 6 months after the control group 
received treatment are presented in Table 7. In combination, 
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Assessed for eligibility (n=40) 
Excluded (n=8) 
Not suitable phobia (n=5) 
Declined to participate (n=3) 
Analysed (n=16) at 2 weeks and 6 months and 9 months 
Analysed n=11 at 12 months 
Retained during treatment (n=16) 
2 weeks post treatment outcome measures (n=16) 
6 month post treatment outcome measures   (n=16) 
Twelve month outcome measured (Target behaviours only) 
(n=11) 
Allocated to intervention (n=16) 
Received allocated intervention (n=16) 
Retained for follow up as control (n=16) 
Outcome measures as control 2 weeks post treatment  
(n=16) 
 Outcome measures as control 6 months post treatment 
(n=16)
Allocated to delayed treatment control group (n=16) 











Control group receive treatment (n=15); one child did not 
receive treatment as there were other treatment priorities 
Two week post treatment outcome measured (Target 
Behaviours only) (n=15) 
Six month post treatment outcome measured (Target 
Behaviours only) (n=8) 
Analysed (n=15) at 2 weeks post treatment; (n=8) at six 
months post treatment 
Fig. 2  Consort diagram
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Fig. 3  a Change in child ratings of their own confidence from treatment session 1 to 4 for the immediate treatment group. b Change in parent’s 
rating of their child’s confidence from treatment session 1 to 4 for the immediate treatment group
Table 3  Target behaviour mean change ratings for immediate treatment and control groups at 2 weeks and at 6 months post treatment with effect 
size and observed power. Lower score indicates greater improvement
Treatment Control Total Effect size 
Cohen’s d
95% CI for Cohen’s 
d
Observed power
n Mean n Mean n Mean Lower Upper
Rating at 2 weeks 16 4.17 (1.27) 16 5.25 (0.77) 32 4.71 (1.17) 1.03 0.291 1.766 .803
Rating at 6 months 16 3.92 (1.63) 15 5.40 (0.86) 31 4.64 (1.50) 1.14 0.377 1.894 .852
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the post treatment data for the immediate treatment and con-
trol groups showed 13/31 (41.9%) children were treatment 
responders at 2 weeks post treatment, and 11/24 (45.8%) 
children at 6 months post treatment.
Discussion
This is the first report of a randomised controlled trial of an 
immersive virtual reality treatment for specific phobia in 
young people with ASD.
The trial results regarding treatment fidelity and trial 
retention support our previous findings of the feasibility and 
acceptability of this novel intervention for specific phobia 
(Maskey et al. 2014). NHS clinicians were keen to refer; 
families were positive about accessing treatment through a 
trial including randomisation. All children and parents in the 
immediate treatment group attended four sessions of treat-
ment. Treatment was delivered with fidelity by 11 assistant 
psychologists and specialist nurses, after a 2 hours training 
workshop and initial supervision. During treatment, most 
children’s rating of their confidence at tackling their goal 
situation increased, an increase reflected in parent ratings. 
Data completeness for the main outcome measure of target 
behaviour rating was excellent.
One-third of children from the treatment group showed 
improvements in their real life targeted phobia, with chil-
dren able to manage everyday activities and situations that 
were not possible previously. By contrast, no children in the 
control group showed improvement in their specific phobia 
during their wait phase of the trial period. Furthermore, five 
control group children showed a clear deterioration in target 
behaviour rating from baseline, compared with one treat-
ment group child. When the control group later received 
treatment, a similar proportion were classified as responders 
as to the immediate treatment group.
More than half the children in the immediate treatment 
group were not rated as ‘responders’. Whilst a success rate 
of 38% with definite positive change on blinded, independ-
ent rating, with a large effect size, is at least comparable 
with other interventions for anxiety (Ung et al. 2015), we 
will explore in a future report factors that may moderate 
responsiveness to the intervention.
Regarding the questionnaire measures, the descriptive 
data indicates that these anxiety tools developed for use 
with typically developing individuals were not sensitive to 
the treatment effect observed in the main target behaviour 
outcome which focused on individualised real life examples. 
While collection of data using these questionnaires seemed 
acceptable to young people and parents, we will assess their 
usefulness as outcome measures in future studies. In line 
with other research investigating treatment of fears and pho-
bias in ASD (Lydon et al. 2015), we conclude that target 
behaviour ratings are the best indicator of real life change 
and will be used as we continue to monitor the effectiveness 
of the treatment. Behaviour vignettes are straightforward to 
collect from parents (by brief telephone interview), can be 
gathered ‘blind’, and are acceptable as indicated by the high 
level of data completeness.
This is a methodologically strong single blind trial, 
including randomisation, delivery of a manualised treatment 
with high fidelity levels, 100% retention, comprehensive out-
come measurement conducted by a blinded assessor, and 
target behaviour ratings evaluated by an independent blinded 
panel. There were possible weaknesses, including the sample 
size, and potential for placebo effect in self-report. Updates 
on participants’ functioning were obtained by parent report, 
which has the potential for bias; direct observations of pro-
gress were not made. Due to the need to accommodate scene 
design and parent availability, there were small differences 
between the time from baseline measurement to treatment, 
and treatment to outcome measurement—although these 
were the same for the treatment and control groups.
Clinical Implications and Future Research
New interventions for anxiety in children with ASD are 
needed. Whilst CBT can be effective, adaptations to CBT 
have been shown to improve the efficacy of this form of 
therapy for autistic people (Lang et al. 2010; Moree and 
Davis 2010; Sofronoff et al. 2005; Weiss et al. 2018). 
The Blue Room VRE treatment conforms with guidance 
Table 4  Target behaviour 
ratings categories (responder, 
no change/equivocal, and 
worse) for immediate treatment 
group at 2 weeks, 6 months and 
12 months post treatment and 
control group
a 1 parent vignette missing
b 5 parent vignettes missing
Target behaviour rating 2 weeks 6 months 12 months
Treatment Control Treatment Control Treatment
n (%) n (%) n (%) n (%)a n (%)b
Treatment responder (1.0–3.0) 4/16 (25.0) 0 6/16 (37.5) 0 4/11 (36.4)
No change/equivocal (3.1–5.9) 11/16 (68.8) 13/16 (81.3) 9/16 (56.3) 10/15 (66.7) 7/11 (63.6)
Symptoms worse than at base-
line (6.0–9.0)
1/16 (6.3) 3/16 (18.7) 1/16 (6.3) 5/15 (33.3) 0
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contained in the UK National Institute for Health and 
Care Excellence (NICE) in Guideline 170 (NICE 2013) 
regarding adaptations to CBT for children with ASD. 
Adaptations included in this treatment included greater 
use of written and visual information, a more cognitively 
concrete and structured approach, and involving a parent/
carer. Additional reasons why virtual reality can improve 
the effectiveness of CBT for children with ASD include 
being able to repeatedly practice anxiety reduction tech-
niques at one level of exposure to enable mastery to be 
achieved before moving up the exposure hierarchy. This 
develops confidence and a feeling of control as the child 
receives controlled exposure. Parents observe sessions and 
gain an understanding of the methods used, which they can 
utilise in real life situations. Virtual reality is increasingly 
being used in mental health therapy with positive effect 
in the neurotypical population (Maples-Keller et al. 2017; 
Botella et al. 2017; Parsons and Rizzo 2008); the results 
from the study presented here illustrate that this type of 
intervention may also be beneficial for people with autism.
In future research, comparing treatment with a group 
receiving traditional CBT only would more directly evaluate 
the additional impact of the VR component. The feasibility 
and data requirements of a cost-effectiveness analysis are 
being assessed. Investigating what adaptations are required 
for the treatment of people with mild or moderate learning 
disability will be important. Characteristics of children and 
families who benefit most from treatment will be studied as 
the treatment is delivered through clinical services, or future 
studies. As clinical delivery of the Newcastle Blue Room 
VRE Treatment progresses, systematic data gathering with 
all children and families is planned.
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